Michael Hertl Selected Research

Pemphigus (Pemphigus Vulgaris)

01/2008	IgG against extracellular subdomains of desmoglein 3 relates to clinical phenotype of pemphigus vulgaris.
08/2007	A single cycle of rituximab for the treatment of severe pemphigus.
03/2007	Detection of low avidity desmoglein 3-reactive T cells in pemphigus vulgaris using HLA-DR beta 1*0402 tetramers.
01/2007	Rituximab (anti-CD20 monoclonal antibody)--ultimate or first choice in pemphigus?
08/2006	IgG reactivity against non-conformational NH-terminal epitopes of the desmoglein 3 ectodomain relates to clinical activity and phenotype of pemphigus vulgaris.
05/2006	Delayed response of oral pemphigus vulgaris to rituximab treatment.
01/2006	Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorption.
08/2005	Ex vivo analysis of desmoglein 1-responsive T-helper (Th) 1 and Th2 cells in patients with pemphigus foliaceus and healthy individuals.
05/2004	Type I regulatory T cells specific for desmoglein 3 are more frequently detected in healthy individuals than in patients with pemphigus vulgaris.
03/2004	T cell recognition of desmoglein 3 peptides in patients with pemphigus vulgaris and healthy individuals.
09/2003	T-cellular autoimmunity against desmogleins in pemphigus, an autoantibody-mediated bullous disorder of the skin.
01/2003	Dichotomy of autoreactive Th1 and Th2 cell responses to desmoglein 3 in patients with pemphigus vulgaris (PV) and healthy carriers of PV-associated HLA class II alleles.

12	Pemphigus (Pemphigus Vulgaris) 01/2008 - 01/2003
4	Bullous Pemphigoid (Pemphigoid) 02/2006 - 07/2002
1	Diabetes Mellitus 09/2008
1	Vesiculobullous Skin Diseases (Subcorneal Pustular Dermatosis) 05/2008
1	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2008
1	Epidermolysis Bullosa Acquisita (Acquired Epidermolysis Bullosa) 02/2007
1	Atopic Dermatitis (Atopic Eczema) 03/2005

5	rituximab (Mabthera)FDA Link 05/2008 - 05/2006
5	Desmoglein 3IBA 01/2008 - 01/2003
4	DesmogleinsIBA 03/2007 - 09/2003
3	AntibodiesIBA 09/2008 - 06/2004
2	Immunoglobulin G (IgG)IBA 01/2008 - 08/2006
2	EpitopesIBA 08/2006 - 02/2006
1	pimecrolimus (Elidel)FDA Link 01/2008
1	HLA-DR Antigens (HLA-DR)IBA 03/2007
1	Monoclonal AntibodiesIBA 02/2007
1	AutoantibodiesIBA 01/2006
1	Laminin (Merosin)IBA 04/2005
1	infliximab (Remicade)FDA Link 03/2005
1	PeptidesIBA 03/2004
1	Serum AlbuminIBA 07/2002